Viridian Therapeutics, Inc./DE Other Nonoperating Income (Expense)
Viridian Therapeutics, Inc./DE (VRDN) reported Other Nonoperating Income (Expense) of -$47.00 thousand for the 3-month period ending 2019-12-31, per its 10-K filed 2020-03-13.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2020-03-13
- Viridian Therapeutics, Inc./DE other nonoperating income (expense) for the quarter ending 2019-12-31 was -$47.00K, a 134.56% decline year-over-year.
- Viridian Therapeutics, Inc./DE other nonoperating income (expense) for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE other nonoperating income (expense) for the quarter ending 2019-06-30 was $46.00K, a 68.71% decline year-over-year.
- Viridian Therapeutics, Inc./DE other nonoperating income (expense) for the quarter ending 2019-03-31 was $107.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$47.00K 10-K · filed 2020-03-13 | -$47.00K derived: sum of 2 quarters · filed 2020-03-13 | -$1.00K derived: sum of 3 quarters · filed 2020-03-13 | $106.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-09-30 | $0.00 10-K · filed 2020-03-13 | $46.00K derived: sum of 2 quarters · filed 2020-03-13 | $153.00K derived: sum of 3 quarters · filed 2020-03-13 | $289.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-06-30 | $46.00K 10-K · filed 2020-03-13 | $153.00K derived: sum of 2 quarters · filed 2020-03-13 | $289.00K derived: sum of 3 quarters · filed 2020-03-13 | $429.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-03-31 | $107.00K 10-K · filed 2020-03-13 | $243.00K derived: sum of 2 quarters · filed 2020-03-13 | $383.00K derived: sum of 3 quarters · filed 2020-03-13 | $530.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-12-31 | $136.00K 10-K · filed 2020-03-13 | $276.00K derived: sum of 2 quarters · filed 2020-03-13 | $423.00K derived: sum of 3 quarters · filed 2020-03-13 | $381.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-09-30 | $140.00K 10-K · filed 2020-03-13 | $287.00K derived: sum of 2 quarters · filed 2020-03-13 | $245.00K derived: sum of 3 quarters · filed 2020-03-13 | $213.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-06-30 | $147.00K 10-K · filed 2020-03-13 | $105.00K derived: sum of 2 quarters · filed 2020-03-13 | $73.00K derived: sum of 3 quarters · filed 2020-03-13 | $128.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-03-31 | -$42.00K 10-K · filed 2020-03-13 | -$74.00K derived: sum of 2 quarters · filed 2020-03-13 | -$19.00K derived: sum of 3 quarters · filed 2020-03-13 | $19.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2017-12-31 | -$32.00K 10-K · filed 2019-03-14 | $23.00K derived: sum of 2 quarters · filed 2019-03-14 | $61.00K derived: sum of 3 quarters · filed 2019-03-14 | $20.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-09-30 | $55.00K 10-K · filed 2019-03-14 | $93.00K derived: sum of 2 quarters · filed 2019-03-14 | $52.00K derived: sum of 3 quarters · filed 2019-03-14 | -$8.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $38.00K 10-K · filed 2019-03-14 | -$3.00K derived: sum of 2 quarters · filed 2019-03-14 | -$63.00K derived: sum of 3 quarters · filed 2019-03-14 | -$134.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-03-31 | -$41.00K 10-K · filed 2019-03-14 | -$101.00K derived: sum of 2 quarters · filed 2019-03-14 | -$172.00K derived: sum of 3 quarters · filed 2019-03-14 | -$246.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2016-12-31 | -$60.00K 10-K · filed 2018-03-15 | -$131.00K derived: sum of 2 quarters · filed 2018-03-15 | -$205.00K derived: sum of 3 quarters · filed 2018-03-15 | -$287.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-09-30 | -$71.00K 10-K · filed 2018-03-15 | -$145.00K derived: sum of 2 quarters · filed 2018-03-15 | -$227.00K derived: sum of 3 quarters · filed 2018-03-15 | |
| 2016-06-30 | -$74.00K 10-K · filed 2018-03-15 | -$156.00K derived: sum of 2 quarters · filed 2018-03-15 | ||
| 2016-03-31 | -$82.00K 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |